Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Induction of myelodysplasia by myeloid-derived suppressor cells
Xianghong Chen, … , Alan List, Sheng Wei
Xianghong Chen, … , Alan List, Sheng Wei
Published October 15, 2013
Citation Information: J Clin Invest. 2013;123(11):4595-4611. https://doi.org/10.1172/JCI67580.
View: Text | PDF
Research Article Hematology Article has an altmetric score of 28

Induction of myelodysplasia by myeloid-derived suppressor cells

  • Text
  • PDF
Abstract

Myelodysplastic syndromes (MDS) are age-dependent stem cell malignancies that share biological features of activated adaptive immune response and ineffective hematopoiesis. Here we report that myeloid-derived suppressor cells (MDSC), which are classically linked to immunosuppression, inflammation, and cancer, were markedly expanded in the bone marrow of MDS patients and played a pathogenetic role in the development of ineffective hematopoiesis. These clonally distinct MDSC overproduce hematopoietic suppressive cytokines and function as potent apoptotic effectors targeting autologous hematopoietic progenitors. Using multiple transfected cell models, we found that MDSC expansion is driven by the interaction of the proinflammatory molecule S100A9 with CD33. These 2 proteins formed a functional ligand/receptor pair that recruited components to CD33’s immunoreceptor tyrosine-based inhibition motif (ITIM), inducing secretion of the suppressive cytokines IL-10 and TGF-β by immature myeloid cells. S100A9 transgenic mice displayed bone marrow accumulation of MDSC accompanied by development of progressive multilineage cytopenias and cytological dysplasia. Importantly, early forced maturation of MDSC by either all-trans-retinoic acid treatment or active immunoreceptor tyrosine-based activation motif–bearing (ITAM-bearing) adapter protein (DAP12) interruption of CD33 signaling rescued the hematologic phenotype. These findings indicate that primary bone marrow expansion of MDSC driven by the S100A9/CD33 pathway perturbs hematopoiesis and contributes to the development of MDS.

Authors

Xianghong Chen, Erika A. Eksioglu, Junmin Zhou, Ling Zhang, Julie Djeu, Nicole Fortenbery, Pearlie Epling-Burnette, Sandra Van Bijnen, Harry Dolstra, John Cannon, Je-in Youn, Sarah S. Donatelli, Dahui Qin, Theo De Witte, Jianguo Tao, Huaquan Wang, Pingyan Cheng, Dmitry I. Gabrilovich, Alan List, Sheng Wei

×

Total citations by year

Year: 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2009 Total
Citations: 5 12 15 26 28 22 15 17 13 18 14 3 1 189
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article (189)

Title and authors Publication Year
The Emerging Role of CD8+ T Cells in Shaping Treatment Outcomes of Patients with MDS and AML
Tasis A, Spyropoulos T, Mitroulis I
Cancers 2025
Accelerated senescence of bone marrow erythrocyte precursors in myelodysplastic syndrome
Liu M, Yang L, Liu Y, Niu H, Zhang M, Shao Z, Xing L, Wang H
Annals of Medicine 2025
A phase 1 study of durvalumab as monotherapy or combined with tremelimumab with or without azacitidine in patients with myelodysplastic syndrome
Garcia-Manero G, Gaddh M, Platzbecker U, Lindsley RC, Larson SM, Chevassut T, Fenaux P, Komrokji R, Lyons R, Al-Kali A, Jiang Y, Bothos J, Townsley DM, Zeidan AM
Annals of Hematology 2025
Bone marrow microenvironment in myelodysplastic neoplasms: insights into pathogenesis, biomarkers, and therapeutic targets
Bahmani F, Shayanmanesh M, Safari M, Alaei A, Yasaman Pouriafar, Rasti Z, Zaker F, Rostami S, Damerchiloo F, Safa M
Cancer Cell International 2025
A correlation of ineffective erythropoiesis and dysregulated signaling pathways in myelodysplastic syndromes/neoplasms
Wu J, Liu J, Chen J, Yang L, Li F, Qin T, Xu Z, Liu J, Zhou J, Shi L, Li B, Xiao Z
Experimental Hematology & Oncology 2025
Myeloid-derived suppressor cells in cancer and cancer therapy.
Lasser SA, Ozbay Kurt FG, Arkhypov I, Utikal J, Umansky V
Nature reviews. Clinical oncology 2024
Engagement of sialylated glycans with Siglec receptors on suppressive myeloid cells inhibits anticancer immunity via CCL2.
Wieboldt R, Sandholzer M, Carlini E, Lin CW, Börsch A, Zingg A, Lardinois D, Herzig P, Don L, Zippelius A, Läubli H, Mantuano NR
Cellular & molecular immunology 2024
First‐in‐human study of JNJ‐67571244, a CD33 × CD3 bispecific antibody, in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome
Narayan R, Piérola AA, Donnellan WB, Yordi AM, Abdul\u2010Hay M, Platzbecker U, Subklewe M, Kadia TM, Alonso\u2010Domínguez JM, McCloskey J, Bradford K, Curtis M, Daskalakis N, Guttke C, Safer K, Hiebert B, Murphy J, Li X, Duchin K, Esteban D
Clinical and Translational Science 2024
MDSC expansion during HIV infection: regulators, ART and immune reconstitution.
Yaseen MM, Abuharfeil NM, Darmani H
Genes and Immunity 2024
Granzymes in health and diseases: the good, the bad and the ugly.
Cigalotto L, Martinvalet D
Frontiers in immunology 2024
S100A9: The Unusual Suspect Connecting Viral Infection and Inflammation.
Boucher J, Gilbert C, Bose S, Tessier PA
Journal of immunology (Baltimore, Md. : 1950) 2024
Immune-monitoring of myelodysplastic neoplasms: Recommendations from the i4MDS consortium.
Tentori CA, Zhao LP, Tinterri B, Strange KE, Zoldan K, Dimopoulos K, Feng X, Riva E, Lim B, Simoni Y, Murthy V, Hayes MJ, Poloni A, Padron E, Cardoso BA, Cross M, Winter S, Santaolalla A, Patel BA, Groarke EM, Wiseman DH, Jones K, Jamieson L, Manogaran C, Daver N, Gallur L, Ingram W, Ferrell PB, Sockel K, Dulphy N, Chapuis N, Kubasch AS, Olsnes AM, Kulasekararaj A, De Lavellade H, Kern W, Van Hemelrijck M, Bonnet D, Westers TM, Freeman S, Oelschlaegel U, Valcarcel D, Raddi MG, Grønbæk K, Fontenay M, Loghavi S, Santini V, Almeida AM, Irish JM, Sallman DA, Young NS, van de Loosdrecht AA, Adès L, Della Porta MG, Cargo C, Platzbecker U, Kordasti S
HemaSphere 2024
Targeting MCL1-driven anti-apoptotic pathways overcomes blast progression after hypomethylating agent failure in chronic myelomonocytic leukemia
Montalban-Bravo G, Thongon N, Rodriguez-Sevilla JJ, Ma F, Ganan-Gomez I, Yang H, Kim YJ, Adema V, Wildeman B, Tanaka T, Darbaniyan F, Al-Atrash G, Dwyer K, Loghavi S, Kanagal-Shamanna R, Song X, Zhang J, Takahashi K, Kantarjian H, Garcia-Manero G, Colla S
Cell reports. Medicine 2024
Glioma-Associated Sialoglycans Drive the Immune Suppressive Phenotype and Function of Myeloid Cells
Cornelissen LA, Santegoets KC, Kers-Rebel ED, Bossmann SA, Ter Laan M, Granado D, Adema GJ
Pharmaceutics 2024
Prototypical innate immune mechanism hijacked by leukemia-initiating mutant stem cells for selective advantage and immune evasion in Ptpn11-associated juvenile myelomonocytic leukemia
Qu CK, Zheng H, Zhao P, Tan Z, Yu WM, Werner J, Stieglitz E, Porter C, Chandrakasan S, Wechsler D, Mendez-Ferrer S
Research Square 2024
Implications for Metabolic Disturbances in Myelodysplastic Syndromes
McGraw KL, Larson DR
Seminars in hematology 2024
Monocytes generated by interleukin-6-treated human hematopoietic stem and progenitor cells secrete calprotectin that inhibits erythropoiesis
Marchand V, Laplane L, Valensi L, Plo I, Aglave M, Silvin A, Pasquier F, Porteu F, Vainchenker W, Selimoglu-Buet D, Droin N, Raslova H, Marcel V, Diaz JJ, Fontenay M, Solary E
iScience 2024
Oxidized Mitochondrial DNA Engages TLR9 to Activate the NLRP3 Inflammasome in Myelodysplastic Syndromes
Ward GA, Dalton RP III, Meyer BS, McLemore AF, Aldrich AL, Lam NB, Onimus AH, Vincelette ND, Trinh TL, Chen X, Calescibetta AR, Christiansen SM, Hou HA, Johnson JO, Wright KL, Padron E, Eksioglu EA, List AF
International journal of molecular sciences 2023
A Killer Disarmed: Natural Killer Cell Impairment in Myelodysplastic Syndrome.
Arellano-Ballestero H, Sabry M, Lowdell MW
Cells 2023
The Role of BCL-2 and PD-1/PD-L1 Pathway in Pathogenesis of Myelodysplastic Syndromes
Kuszczak B, Wróbel T, Wicherska-Pawłowska K, Rybka J
International journal of molecular sciences 2023
The roles of toll-like receptor 4, CD33, CD68, CD69, or CD147/EMMPRIN for monocyte activation by the DAMP S100A8/S100A9
Möller A, Jauch-Speer SL, Gandhi S, Vogl T, Roth J, Fehler O
Frontiers in immunology 2023
Modulation of T-cell function by myeloid-derived suppressor cells in hematological malignancies
Bhardwaj V, Ansell SM
Frontiers in Cell and Developmental Biology 2023
Immunogenic Cell Death in Hematological Malignancy Therapy
Liu Z, Xu X, Liu K, Zhang J, Ding D, Fu R
Advanced Science 2023
High BM plasma S100A8/A9 is associated with a perturbed microenvironmentand poor prognosis in myelodysplastic syndromes
Wang YH, Lin CC, Yao CY, Amaral FM, Yu SC, Kao CJ, Shih PT, Hou HA, Chou WC, Tien HF
Blood Advances 2023
Role of innate immunological/inflammatory pathways in myelodysplastic syndromes and AML: a narrative review
Vegivinti CT, Keesari PR, Veeraballi S, Martins Maia CM, Mehta AK, Lavu RR, Thakur RK, Tella SH, Patel R, Kakumani VK, Pulakurthi YS, Aluri S, Aggarwal RK, Ramachandra N, Zhao R, Sahu S, Shastri A, Verma A
Experimental Hematology and Oncology 2023
Immune escape and resistance to immunotherapy in mismatch repair deficient tumors
Mestrallet G, Brown M, Bozkus CC, Bhardwaj N
Frontiers in immunology 2023
The recent progress of myeloid‐derived suppressor cell and its targeted therapies in cancers
Ren R, Xiong C, Ma R, Wang Y, Yue T, Yu J, Shao B
2023
Immune dysregulation and potential targeted therapy in myelodysplastic syndrome
Zhang X, Yang X, Ma L, Zhang Y, Wei J
Therapeutic Advances in Hematology 2023
S100A8 and S100A9 in Hematologic Malignancies: From Development to Therapy
Razmkhah F, Kim S, Lim S, Dania AJ, Choi J
International journal of molecular sciences 2023
Immune checkpoints represent a promising breakthrough in targeted therapy and prognosis of myelodysplastic syndrome
Guo X, Yu S, Ren X, Li L
Heliyon 2023
SRSF2 mutation reduces polycythemia and impairs hematopoietic progenitor functions in JAK2V617F-driven myeloproliferative neoplasm
Yang Y, Abbas S, Sayem MA, Dutta A, Mohi G
Blood Cancer Journal 2023
A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agents.
Bewersdorf JP, Shallis RM, Sharon E, Park S, Ramaswamy R, Roe CE, Irish JM, Caldwell A, Wei W, Yacoub A, Madanat YF, Zeidner JF, Altman JK, Odenike O, Yerrabothala S, Kovacsovics T, Podoltsev NA, Halene S, Little RF, Piekarz R, Gore SD, Kim TK, Zeidan AM
Annals of Hematology 2023
TIRAP drives myelosuppression through an Ifnγ–Hmgb1 axis that disrupts the endothelial niche in mice
A Gopal, R Ibrahim, M Fuller, P Umlandt, J Parker, J Tran, L Chang, J Wegrzyn-Woltosz, J Lam, J Li, M Lu, A Karsan
Journal of Experimental Medicine 2022
SF3B1 mutations induce pathogenic activation of targetable inflammatory immune signaling in MDS
Gaurav Choudhary, Andrea Pellagatti, Bogos Agianian, Molly Smith, Tushar Bhagat, Shanisha Gordon-Mitchell, Sanjay Pandey, Nishi Shah, Srinivas Aluri, Leya Schwartz, Violetta Steeples, Robert Booher, Murali Ramachandra, Maria Samson, Milagros Carbajal, Kith Pradhan, Teresa Bowman, Manoj M. Pillai, Britta Will, Amittha Wickrema, Aditi Shastri, Robert Martell, Ulrich Steidl, Evripidis Gavathiotis, Jacqueline Boultwood, Daniel Starczynowski, Amit Verma
eLife 2022
Murine myeloid derived suppressor cells possess a range of suppressive mechanisms—Granzyme B is not among them
E Tibbs, X Cao
Cancer Immunology, Immunotherapy 2022
A Structural Perspective on Calprotectin as a Ligand of Receptors Mediating Inflammation and Potential Drug Target
V Garcia, Y Perera, W Chazin
Biomolecules 2022
Emerging Canonical and Non-Canonical Roles of Granzyme B in Health and Disease
E Tibbs, X Cao
Cancers 2022
Emerging immuno-oncology targets in Myelodysplastic Syndromes (MDS)
M Mann, A Brunner
Current Problems in Cancer 2022
Microenvironmental Features Driving Immune Evasion in Myelodysplastic Syndromes and Acute Myeloid Leukemia
Barakos GP, Hatzimichael E
Diseases 2022
Inflammasome Activation in Myeloid Malignancies-Friend or Foe?
Andina N, Bonadies N, Allam R
Frontiers in Cell and Developmental Biology 2022
S100A9-CXCL12 activation in BRCA1-mutant breast cancer promotes an immunosuppressive microenvironment associated with resistance to immunotherapy
Li J, Shu X, Xu J, Su SM, Chan UI, Mo L, Liu J, Zhang X, Adhav R, Chen Q, Wang Y, An T, Zhang X, Lyu X, Li X, Lei JH, Miao K, Sun H, Xing F, Zhang A, Deng C, Xu X
Nature Communications 2022
Targeting PD-1/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia
Yang X, Ma L, Zhang X, Huang L, Wei J
Experimental Hematology and Oncology 2022
Immunodepletion of MDSC by AMV564, a novel bivalent, bispecific CD33/CD3 T cell engager, ex vivo in MDS and melanoma
Cheng P, Chen X, Dalton R, Calescibetta A, So T, Gilvary D, Ward G, Smith V, Eckard S, Fox JA, Guenot J, Markowitz J, Cleveland JL, Wright KL, List AF, Wei S, Eksioglu EA
Molecular Therapy 2022
Somatic gene mutations expose cytoplasmic DNA to co-opt the cGAS-STING-NLRP3 axis in Myelodysplastic Syndromes
Amy F McLemore, Hsin-An Hou, Benjamin S Meyer, Nghi B. Lam, Grace A. Ward, Amy Aldrich, Matthew A. Rodrigues, Alexis Vedder, Ling Zhang, Eric Padron, Nicole Vincelette, David Sallman, Omar Abdel-Wahab, Alan List, Kathy L McGraw
JCI Insight 2022
The Innate Immune Protein Calprotectin Interacts With and Encases Biofilm Communities of Pseudomonas aeruginosa and Staphylococcus aureus
Baishya J, Everett JA, Chazin WJ, Rumbaugh KP, Wakeman CA
Frontiers in Cellular and Infection Microbiology 2022
Cooperation between KDM6B overexpression and TET2 deficiency in the pathogenesis of chronic myelomonocytic leukemia.
Wei Y, Kanagal-Shamanna R, Zheng H, Bao N, Lockyer PP, Class CA, Darbaniyan F, Lu Y, Lin K, Yang H, Montalban-Bravo G, Ganan-Gomez I, Soltysiak KA, Do KA, Colla S, Garcia-Manero G
Leukemia 2022
The immunomodulatory role of all-trans retinoic acid in tumor microenvironment.
Bi G, Liang J, Bian Y, Shan G, Besskaya V, Wang Q, Zhan C
Clinical and Experimental Medicine 2022
Myeloid-derived suppressor cells in hematologic malignancies: two sides of the same coin.
Yu S, Ren X, Li L
Experimental Hematology and Oncology 2022
Diagnosis of Myelodysplastic Syndromes: From Immunological Observations to Clinical Applications.
Simoni Y, Chapuis N
2022
Myeloid-Derived Suppressor Cells: New Insights into the Pathogenesis and Therapy of MDS
Velegraki M, Stiff A, Papadaki HA, Li Z
Journal of Clinical Medicine 2022
Pharmacological modulation of myeloid-derived suppressor cells to dampen inflammation.
van Geffen C, Heiss C, Deißler A, Kolahian S
Frontiers in immunology 2022
New Perspectives on Myeloid-Derived Suppressor Cells and Their Emerging Role in Haematology
Bizymi N, Matthaiou AM, Matheakakis A, Voulgari I, Aresti N, Zavitsanou K, Karasachinidis A, Mavroudi I, Pontikoglou C, Papadaki HA
Journal of Clinical Medicine 2022
Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy.
Wu Y, Yi M, Niu M, Mei Q, Wu K
Molecular Cancer 2022
A phase I/II multicenter, open-label, dose escalation and randomized trial of BI 836858 in patients with low- or intermediate-1-risk myelodysplastic syndrome.
Komrokji RS, Carraway HE, Germing U, Wermke M, Zeidan AM, Fu E, Rüter B, Burkard U, Osswald A, Foran JM
Haematologica 2022
Immune Modulation by Myeloid-Derived Suppressor Cells in Diabetic Kidney Disease
Hsieh CC, Chang CC, Hsu YC, Lin CL
International journal of molecular sciences 2022
The prognostic effects of circulating myeloid-derived suppressor cells in non-small cell lung cancer: systematic review and meta-analysis.
Bronte G, Calabrò L, Olivieri F, Procopio AD, Crinò L
Clinical and Experimental Medicine 2022
Bone Marrow Immune Microenvironment in Myelodysplastic Syndromes
Kouroukli O, Symeonidis A, Foukas P, Maragkou MK, Kourea EP
Cancers 2022
Biological drivers of clinical phenotype in myelofibrosis.
Mascarenhas J, Gleitz HFE, Chifotides HT, Harrison CN, Verstovsek S, Vannucchi AM, Rampal RK, Kiladjian JJ, Vainchenker W, Hoffman R, Schneider RK, List AF
Leukemia 2022
IRAK1 and IRAK4 as emerging therapeutic targets in hematologic malignancies
J Bennett, DT Starczynowski
Current Opinion in Hematology 2021
Crucial roles of different RNA-binding hnRNP proteins in Stem Cells
W Xie, H Zhu, M Zhao, L Wang, S Li, C Zhao, Y Zhou, B Zhu, X Jiang, W Liu, C Ren
International journal of biological sciences 2021
Constitutively Activated DAP12 Induces Functional Anti-Tumor Activation and Maturation of Human Monocyte-Derived DC
R Dalton, A Calescibetta, JM Zhou, M Maurin, G Ward, TL Trinh, N Tu, D Gilvary, X Chen, P Cheng, E Kostenko, S Wei, KL Wright, EA Eksioglu
International journal of molecular sciences 2021
Inflammation-Induced Tumorigenesis and Metastasis
S Hibino, T Kawazoe, H Kasahara, S Itoh, T Ishimoto, M Sakata-Yanagimoto, K Taniguchi
International journal of molecular sciences 2021
COVID-19 is a systemic vascular hemopathy: insight for mechanistic and clinical aspects
DM Smadja, SJ Mentzer, M Fontenay, MA Laffan, M Ackermann, J Helms, D Jonigk, R Chocron, GB Pier, N Gendron, S Pons, JL Diehl, C Margadant, C Guerin, EJ Huijbers, A Philippe, N Chapuis, P Nowak-Sliwinska, C Karagiannidis, O Sanchez, P Kümpers, D Skurnik, AM Randi, AW Griffioen
Angiogenesis 2021
The impact of metal availability on immune function during infection
AJ Monteith, EP Skaar
Trends in endocrinology and metabolism: TEM 2021
S100A9 Activates the Immunosuppressive Switch Through the PI3K/Akt Pathway to Maintain the Immune Suppression Function of Testicular Macrophages
ZP Fan, ML Peng, YY Chen, YZ Xia, CY Liu, K Zhao, HP Zhang
Frontiers in immunology 2021
The Role and Therapeutic Targeting of JAK/STAT Signaling in Glioblastoma
A Ou, M Ott, D Fang, AB Heimberger
Cancers 2021
Interaction Networks Converging on Immunosuppressive Roles of Granzyme B: Special Niches Within the Tumor Microenvironment
W Wang, R Zou, Y Qiu, J Liu, Y Xin, T He, Z Qiu
Frontiers in immunology 2021
S100A8/A9 in COVID-19 pathogenesis: Impact on clinical outcomes
L Mellett, SA Khader
Cytokine & Growth Factor Reviews 2021
Myeloid-Derived Suppressor Cells and Mesenchymal Stem/Stromal Cells in Myeloid Malignancies
S Kapor, JF Santibanez
Journal of Clinical Medicine 2021
Increased Circulating CD4+CXCR5+ Cells and IgG4 Levels in Patients with Myelodysplastic Syndrome with Autoimmune Diseases
N Xiao, X He, H Niu, H Yu, N Cui, H Li, L Yan, Z Shao, L Xing, H Wang, S Li
Journal of Immunology Research 2021
Regulation of prognosis-related Siglecs in the glioma microenvironment
R Mao, L Zhou, Y Yang, P Wang, H Lin, J Zheng, G Lv, D Zhou
Journal of Cancer Research and Clinical Oncology 2021
Increased Circulating of CD54highCD181low Neutrophils in Myelodysplastic Syndrome
L Yang, H Li, Y Liu, X Xie, H Zhang, H Niu, Z Shao, L Xing, H Wang
Frontiers in Oncology 2021
Immune checkpoint blockade in triple negative breast cancer influenced by B cells through myeloid-derived suppressor cells
A Vito, O Salem, N El-Sayes, IP MacFawn, AL Portillo, K Milne, D Harrington, AA Ashkar, Y Wan, ST Workenhe, BH Nelson, TC Bruno, KL Mossman
2021
Calprotectin: from biomarker to biological function
A Jukic, L Bakiri, EF Wagner, H Tilg, TE Adolph
Gut 2021
Pathogenic Roles of S100A8 and S100A9 Proteins in Acute Myeloid and Lymphoid Leukemia: Clinical and Therapeutic Impacts
J Mondet, S Chevalier, P Mossuz
Molecules (Basel, Switzerland) 2021
From Immune Dysregulations to Therapeutic Perspectives in Myelodysplastic Syndromes: A Review
T Comont, E Treiner, F Vergez
Diagnostics 2021
Therapeutic targeting of the inflammasome in myeloid malignancies
S Chakraborty, LC Shapiro, S de Oliveira, B Rivera-Pena, A Verma, A Shastri
Blood Cancer Journal 2021
Suprabasin—A Review
M Pribyl, Z Hodny, I Kubikova
Genes & development 2021
Immune Therapies for Myelodysplastic Syndromes and Acute Myeloid Leukemia
S Kapoor, G Champion, A Basu, A Mariampillai, MJ Olnes
Cancers 2021
Sequential CRISPR gene editing in human iPSCs charts the clonal evolution of myeloid leukemia and identifies early disease targets
T Wang, AR Pine, AG Kotini, H Yuan, L Zamparo, DT Starczynowski, C Leslie, EP Papapetrou
Cell Stem Cell 2021
Nature or Nurture? Role of the Bone Marrow Microenvironment in the Genesis and Maintenance of Myelodysplastic Syndromes
SA Mian, D Bonnet
Cancers 2021
Oxidized mitochondrial DNA released after inflammasome activation is a disease biomarker for myelodysplastic syndromes
GA Ward, KL McGraw, F Abbas-Aghababazadeh, BS Meyer, AF McLemore, ND Vincelette, NB Lam, AL Aldrich, NH Ali, E Padron, J Pinilla-Ibarz, E Masala, V Santini, O Kosmider, M Fontenay, P Fenaux, J Johnson, BL Fridley, AF List
Blood Advances 2021
Landscape of Myeloid-derived Suppressor Cell in Tumor Immunotherapy
Z Hao, R Li, Y Wang, S Li, Z Hong, Z Han
Biomarker Research 2021
Current Limitations and Perspectives of Chimeric Antigen Receptor-T-Cells in Acute Myeloid Leukemia
M Maucher, M Srour, S Danhof, H Einsele, M Hudecek, I Yakoub-Agha
Cancers 2021
CD123-Directed Bispecific Antibodies for Targeting MDS Clones and Immunosuppressive Myeloid-Derived Suppressor Cells (MDSC) in High-Risk Adult MDS Patients
Uckun FM, Watts J
2021
Stem Cells in the Myelodysplastic Syndromes
Zhan D, Park CY
2021
Mesenchymal stromal cells shape the MDS microenvironment by inducing suppressive monocytes that dampen NK cell function
Dhifaf Sarhan, Jinhua Wang, Upasana Sunil Arvindam, Caroline Hallstrom, Michael R. Verneris, Bartosz Grzywacz, Erica Warlick, Bruce R. Blazar, Jeffrey S. Miller
JCI Insight 2020
Aberrantly elevated suprabasin in the bone marrow as a candidate biomarker of advanced disease state in myelodysplastic syndromes
M Pribyl, S Hubackova, A Moudra, M Vancurova, H Polackova, T Stopka, A Jonasova, R Bokorova, O Fuchs, J Stritesky, B Salovska, J Bartek, Z Hodny
Molecular Oncology 2020
Mass cytometry defines distinct immune profile in germinal center B-cell lymphomas
M Roussel, F Lhomme, CE Roe, T Bartkowiak, P Gravelle, C Laurent, T Fest, JM Irish
Cancer Immunology, Immunotherapy 2020
The Engagement Between MDSCs and Metastases: Partners in Crime
R Trovato, S Canè, V Petrova, S Sartoris, S Ugel, FD Sanctis
Frontiers in Oncology 2020
Contribution of Aberrant Toll Like Receptor Signaling to the Pathogenesis of Myelodysplastic Syndromes
LC Paracatu, LG Schuettpelz
Frontiers in immunology 2020
Immunotherapy in Myeloproliferative Diseases
LM Braun, R Zeiser
Cells 2020
S100-Alarmins Are Essential Pilots of Postnatal Innate Immune Adaptation
D Viemann
Frontiers in immunology 2020
Myelodysplastische Syndrome
A Giagounidis
Der Internist 2020
Dynamic responses of the haematopoietic stem cell niche to diverse stresses
A Batsivari, ML Haltalli, D Passaro, C Pospori, CL Celso, D Bonnet
Nature Cell Biology 2020
Inhibition of LSD1 in MDS progenitors restores differentiation of CD141Hi conventional dendritic cells
P Srivastava, SL Tzetzo, EC Gomez, KH Eng, SN Sait, JB Kuechle, PK Singh, KD Jong, KR Wiatrowski, J Peresie, A Dimitroff, ML Lynch, J Wang, SI Abrams, EA Griffiths, MJ Nemeth
Leukemia 2020
TIFAB Regulates USP15-Mediated p53 Signaling during Stressed and Malignant Hematopoiesis
M Niederkorn, K Hueneman, K Choi, ME Varney, L Romano, MA Pujato, KD Greis, J Inoue, R Meetei, DT Starczynowski
Cell Reports 2020
Novel combinations to improve hematopoiesis in myelodysplastic syndrome
K Syed, S Naguib, ZJ Liu, L Cimmino, FC Yang
Stem Cell Research & Therapy 2020
SETD2 deficiency accelerates MDS-associated leukemogenesis via S100a9 in NHD13 mice and predicts poor prognosis in MDS
BY Chen, J Song, CL Hu, SB Chen, Q Zhang, CH Xu, JC Wu, D Hou, M Sun, YL Zhang, N Liu, PC Yu, P Liu, LJ Zong, JY Zhang, RF Dai, F Lan, QH Huang, SJ Zhang, SD Nimer, Z Chen, SJ Chen, XJ Sun, L Wang
Blood 2020
Genetics of progression from MDS to secondary leukemia
AJ Menssen, MJ Walter
Blood 2020
Regulation of the Bone Marrow Niche by Inflammation
I Mitroulis, L Kalafati, M Bornhäuser, G Hajishengallis, T Chavakis
Frontiers in immunology 2020
Severe ineffective erythropoiesis discriminates prognosis in myelodysplastic syndromes: analysis based on 776 patients from a single centre
H Huang, C Xu, J Gao, B Li, T Qin, Z Xu, S Ren, Y Zhang, M Jiao, S Qu, L Pan, N Hu, J Liu, W Cai, Y Zhang, D Wu, P Zhang, RP Gale, G Huang, J Zhou, L Shi, Z Xiao
Blood Cancer Journal 2020
Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19
A Silvin, N Chapuis, G Dunsmore, AG Goubet, A Dubuisson, L Derosa, C Almire, C Hénon, O Kosmider, N Droin, P Rameau, C Catelain, A Alfaro, C Dussiau, C Friedrich, E Sourdeau, N Marin, TA Szwebel, D Cantin, L Mouthon, D Borderie, M Deloger, D Bredel, S Mouraud, D Drubay, M Andrieu, AS Lhonneur, V Saada, A Stoclin, C Willekens, F Pommeret, F Griscelli, LG Ng, Z Zhang, P Bost, I Amit, F Barlesi, A Marabelle, F Pène, B Gachot, F André, L Zitvogel, F Ginhoux, M Fontenay, E Solary
Cell 2020
Myeloid-derived suppressor cell cytokine secretion as prognostic factor in myelodysplastic syndromes
D Han, J Tao, R Fu, Z Shao
Innate immunity 2020
Monocytic myeloid‐derived suppressor cells reflect tuberculosis severity and are influenced by cyclooxygenase‐2 inhibitors
MJ Jørgensen, S Jenum, K Tonby, R Mortensen, G Walzl, ND Plessis, AM DyrholRiise
Journal of leukocyte biology 2020
The immunology of SARS-CoV-2 infections and vaccines
L Grigoryan, B Pulendran
Seminars in Immunology 2020
Clinical Response to the CD95-Ligand Inhibitor Asunercept Is Defined by a Pro-Inflammatory Serum Cytokine Profile
A Radujkovic, T Boch, F Nolte, D Nowak, C Kunz, A Gieffers, C Müller-Tidow, P Dreger, WK Hofmann, T Luft
Cancers 2020
Neutrophil Phenotypes in Coronary Artery Disease
P Maréchal, J Tridetti, M Nguyen, O Wéra, Z Jiang, M Gustin, A Donneau, C Oury, P Lancellotti
Journal of Clinical Medicine 2020
Hippo kinase loss contributes to del(20q) hematologic malignancies through chronic innate immune activation
SA Stoner, M Yan, KT Liu, KI Arimoto, T Shima, HY Wang, DT Johnson, R Bejar, C Jamieson, KL Guan, DE Zhang
Blood 2019
Calcium-Binding Proteins of the EF-Hand Superfamily: From Basics to Medical Applications
CW Heizmann
2019
Perforin and Granzyme B Expressed by Murine Myeloid-Derived Suppressor Cells: A Study on Their Role in Outgrowth of Cancer Cells
I Dufait, J Pardo, D Escors, YD Vlaeminck, H Jiang, M Keyaerts, MD Ridder, K Breckpot
Cancers 2019
Expression profiling of immune inhibitory Siglecs and their ligands in patients with glioma
KC Santegoets, PR Gielen, C Büll, BM Schulte, ED Kers-Rebel, B Küsters, SA Bossman, M ter Laan, P Wesseling, GJ Adema
Cancer Immunology, Immunotherapy 2019
Myeloid-Derived Suppressor Cells in Hematologic Diseases: Promising Biomarkers and Treatment Targets
N Bizymi, S Bjelica, AO Kittang, S Mojsilovic, M Velegraki, C Pontikoglou, M Roussel, E Ersvær, JF Santibañez, M Lipoldová, HA Papadaki
2019
Flaming and fanning: The Spectrum of inflammatory influences in myelodysplastic syndromes
T Banerjee, LM Calvi, MW Becker, JL Liesveld
Blood Reviews 2019
The inflammatory cytokine profile of myelodysplastic syndromes: A meta-analysis
X Shi, Y Zheng, L Xu, C Cao, B Dong, X Chen
Medicine 2019
Myeloid Derived Suppressor Cells Expansion Persists After Early ART and May Affect CD4 T Cell Recovery
C Agrati, N Tumino, V Bordoni, C Pinnetti, A Sabatini, A Amendola, I Abbate, P Lorenzini, A Mondi, R Casetti, E Cimini, G Grassi, A Antinori, A Sacchi
Frontiers in immunology 2019
Myeloid-derived suppressor cells in hematological malignancies: friends or foes
M Lv, K Wang, X Huang
Journal of Hematology & Oncology 2019
Inflammatory bone marrow microenvironment
NB Leimkühler, RK Schneider
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2019
A New Approach for the Diagnosis of Myelodysplastic Syndrome Subtypes Based on Protein Interaction Analysis
L Chrastinová, O Pastva, M Bocková, NS Lynn, P Šácha, M Hubálek, J Suttnar, R Kotlín, J Štikarová, A Hlaváčková, K Pimková, J Čermák, J Homola, JE Dyr
Scientific Reports 2019
The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes.
Sallman DA, List A
Blood 2019
S100A9-induced overexpression of PD-1/PD-L1 contributes to ineffective hematopoiesis in myelodysplastic syndromes.
Cheng P, Eksioglu EA, Chen X, Kandell W, Le Trinh T, Cen L, Qi J, Sallman DA, Zhang Y, Tu N, Adams WA, Zhang C, Liu J, Cleveland JL, List AF, Wei S
Leukemia 2019
BID-ding on necroptosis in MDS
Croker BA, Kelliher MA
Blood 2019
The role of innate immunity in MDS pathogenesis
Sallman DA, List A
HemaSphere 2019
Hypersialylation in Cancer: Modulation of Inflammation and Therapeutic Opportunities
E Rodrigues, M Macauley
Cancers 2018
Disordered Immune Regulation and its Therapeutic Targeting in Myelodysplastic Syndromes
KS Ivy, PB Ferrell
Current Hematologic Malignancy Reports 2018
Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes
N Daver, P Boddu, G Garcia-Manero, SS Yadav, P Sharma, J Allison, H Kantarjian
Leukemia 2018
The bone-marrow niche in MDS and MGUS: implications for AML and MM
IM Ghobrial, A Detappe, KC Anderson, DP Steensma
Nature Reviews Clinical Oncology 2018
STAT3 in Tumor-Associated Myeloid Cells: Multitasking to Disrupt Immunity
YL Su, S Banerjee, S White, M Kortylewski
International journal of molecular sciences 2018
Immunomodulatory Function of Myeloid-Derived Suppressor Cells during B Cell-Mediated Immune Responses
B Özkan, H Lim, SG Park
International journal of molecular sciences 2018
Age-related inflammatory bone marrow microenvironment induces ineffective erythropoiesis mimicking del(5q) MDS
Y Mei, B Zhao, AA Basiorka, J Yang, L Cao, J Zhang, A List, P Ji
Leukemia 2018
Cancer immune therapy for myeloid malignancies: present and future
MO Holmström, HC Hasselbalch
Seminars in Immunopathology 2018
Secretory IgM Exacerbates Tumor Progression by Inducing Accumulations of MDSCs in Mice
CH Tang, S Chang, A Hashimoto, YJ Chen, CW Kang, AR Mato, JR Valle, DI Gabrilovich, CC Hu
Cancer immunology research 2018
Chronic immune response dysregulation in MDS pathogenesis
L Barreyro, TM Chlon, DT Starczynowski
Blood 2018
The orphan nuclear receptor EAR-2 (NR2F6) inhibits hematopoietic cell differentiation and induces myeloid dysplasia in vivo
CV Ichim, DD Dervovic, LS Chan, CJ Robertson, A Chesney, MD Reis, RA Wells
Biomarker Research 2018
Clonal Hematopoiesis in Aging.
Park SJ, Bejar R
Current Stem Cell Reports 2018
Transforming growth factor β1-mediated functional inhibition of mesenchymal stromal cells in myelodysplastic syndromes and acute myeloid leukemia
Geyh S, Rodríguez-Paredes M, Jäger P, Koch A, Bormann F, Gutekunst J, Zilkens C, Germing U, Kobbe G, Lyko F, Haas R, Schroeder T
Haematologica 2018
KDM6B overexpression activates innate immune signaling and impairs hematopoiesis in mice.
Wei Y, Zheng H, Bao N, Jiang S, Bueso-Ramos CE, Khoury J, Class C, Lu Y, Lin K, Yang H, Ganan-Gomez I, Starczynowski DT, Do KA, Colla S, Garcia-Manero G
Blood Advances 2018
Novel Strategies for Peptide-Based Vaccines in Hematological Malignancies.
Klausen U, Holmberg S, Holmström MO, Jørgensen NGD, Grauslund JH, Svane IM, Andersen MH
Frontiers in immunology 2018
The Rising Era of Immune Checkpoint Inhibitors in Myelodysplastic Syndromes.
Chokr N, Patel R, Wattamwar K, Chokr S
Advances in Hematology 2018
Old Dogs, New Tricks: Revisiting Immune Modulatory Approaches for Myelodysplastic Syndromes.
Götze KS, Platzbecker U
HemaSphere 2018
Targeting innate immunity to downmodulate adaptive immunity and reverse type 1 diabetes
A Itoh, WM Ridgway
ImmunoTargets and Therapy 2017
MUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemia
AR Pyzer, D Stroopinsky, H Rajabi, A Washington, A Tagde, M Coll, J Fung, MP Bryant, L Cole, K Palmer, P Somaiya, RK Leaf, M Nahas, A Apel, S Jain, M McMasters, L Mendez, J Levine, R Joyce, J Arnason, PP Pandolfi, D Kufe, J Rosenblatt, D Avigan
Blood 2017
Stem and progenitor cell alterations in myelodysplastic syndromes
A Shastri, B Will, U Steidl, A Verma
Blood 2017
Novel therapeutic approach to improve hematopoiesis in low risk MDS by targeting MDSCs with the Fc-engineered CD33 antibody BI 836858
EA Eksioglu, X Chen, KH Heider, B Rueter, KL McGraw, AA Basiorka, M Wei, A Burnette, P Cheng, J Lancet, R Komrokji, J Djeu, A List, S Wei
Leukemia 2017
The microenvironment in myelodysplastic syndromes: niche-mediated disease initiation and progression
AJ Li, LM Calvi
Experimental Hematology 2017
S100A8/A9 increases the mobilization of pro-inflammatory Ly6Chigh monocytes to the synovium during experimental osteoarthritis
NA Cremers, MH van Bosch, S Dalen, ID Ceglie, G Ascone, F de Loo, M Koenders, P der Kraan, A Sloetjes, T Vogl, J Roth, EJ Geven, AB Blom, PL van Lent
Arthritis Research & Therapy 2017
Immunotherapeutic Concepts to Target Acute Myeloid Leukemia: Focusing on the Role of Monoclonal Antibodies, Hypomethylating Agents and the Leukemic Microenvironment
O Gbolahan, A Zeidan, M Stahl, MA Zaid, S Farag, S Paczesny, H Konig
International journal of molecular sciences 2017
Pro-inflammatory proteins S100A9 and tumor necrosis factor-α suppress erythropoietin elaboration in myelodysplastic syndromes
T Cluzeau, KL McGraw, B Irvine, E Masala, L Ades, AA Basiorka, J Maciejewski, P Auberger, S Wei, P Fenaux, V Santini, A List
Haematologica 2017
NY-ESO-1 Vaccination in Combination with Decitabine Induces Antigen-Specific T-lymphocyte Responses in Patients with Myelodysplastic Syndrome
EA Griffiths, P Srivastava, J Matsuzaki, Z Brumberger, ES Wang, J Kocent, A Miller, GW Roloff, HY Wong, BE Paluch, LG Lutgen-Dunckley, BL Martens, K Odunsi, AR Karpf, CS Hourigan, MJ Nemeth
Clinical cancer research 2017
Mass cytometry deep phenotyping of human mononuclear phagocytes and myeloid-derived suppressor cells from human blood and bone marrow.
Roussel M, Ferrell PB Jr, Greenplate AR, Lhomme F, Le Gallou S, Diggins KE, Johnson DB, Irish JM
Journal of leukocyte biology 2017
骨髓增生异常综合征骨髓微环境异常的研究进展
2017
[Research progress of bone marrow microenvironment abnormalities in myelodysplastic syndrome].
Dong PY, Huang LF, Sun HY
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 2017
Is Disease-Specific Immunotherapy a Potential Reality for MDS?
Sallman DA, Davila ML
Clinical Lymphoma, Myeloma & Leukemia 2017
Adaptive NK Cells with Low TIGIT Expression Are Inherently Resistant to Myeloid-Derived Suppressor Cells
D Sarhan, F Cichocki, B Zhang, A Yingst, SR Spellman, S Cooley, MR Verneris, BR Blazar, JS Miller
Cancer research 2016
Treatment options for patients with myelodysplastic syndromes after hypomethylating agent failure
HE Carraway
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2016
The Role of Toll-Like Receptors in Hematopoietic Malignancies
DA Monlish, ST Bhatt, LG Schuettpelz
Frontiers in immunology 2016
Mesenchymal Stem and Progenitor Cells in Normal and Dysplastic Hematopoiesis—Masters of Survival and Clonality?
L Pleyer, P Valent, R Greil
International journal of molecular sciences 2016
Improving cancer immunotherapy by targeting the STATe of MDSCs
N Haas, C Koning, L Spilgies, IJ de Vries, SV Hato
OncoImmunology 2016
Rps14 haploinsufficiency causes a block in erythroid differentiation mediated by S100A8 and S100A9
RK Schneider, M Schenone, MV Ferreira, R Kramann, CE Joyce, C Hartigan, F Beier, TH Brümmendorf, U Germing, U Platzbecker, G Büsche, R Knüchel, MC Chen, CS Waters, E Chen, LP Chu, CD Novina, RC Lindsley, SA Carr, BL Ebert
Nature Medicine 2016
Ubiquitination of hnRNPA1 by TRAF6 links chronic innate immune signaling with myelodysplasia
J Fang, LC Bolanos, K Choi, X Liu, S Christie, S Akunuru, R Kumar, D Wang, X Chen, KD Greis, P Stoilov, MD Filippi, JP Maciejewski, G Garcia-Manero, MT Weirauch, N Salomonis, H Geiger, Y Zheng, DT Starczynowski
Nature Immunology 2016
Context Matters: Distinct Disease Outcomes as a Result of Crebbp Hemizygosity in Different Mouse Bone Marrow Compartments
T Zhou, SN Perez, Z Cheng, MC Kinney, ME Lemieux, LM Scott, VI Rebel, F Bertolini
PloS one 2016
CD14 Is a Co-Receptor for TLR4 in the S100A9-Induced Pro-Inflammatory Response in Monocytes
Z He, M Riva, P Björk, K Swärd, M Mörgelin, T Leanderson, F Ivars, A Haziot
PloS one 2016
Down-regulation of EZH2 expression in myelodysplastic syndromes
M Cabrero, Y Wei, H Yang, I Ganan-Gomez, Z Bohannan, S Colla, M Marchesini, GM Bravo, K Takahashi, C Bueso-Ramos, G Garcia-Manero
Leukemia Research 2016
Unraveling the Pathogenesis of MDS: The NLRP3 Inflammasome and Pyroptosis Drive the MDS Phenotype
DA Sallman, T Cluzeau, AA Basiorka, A List
Frontiers in Oncology 2016
The Systemic Profile of Soluble Immune Mediators in Patients with Myelodysplastic Syndromes
A Kittang, K Sand, A Brenner, K Rye, Ø Bruserud
International journal of molecular sciences 2016
Reduced potency of cytotoxic T lymphocytes from patients with high-risk myelodysplastic syndromes
K Sand, J Theorell, Ø Bruserud, YT Bryceson, AO Kittang
Cancer Immunology, Immunotherapy 2016
Bone Marrow Immunity and Myelodysplasia
C Lambert, Y Wu, C Aanei
Frontiers in Oncology 2016
Myelodysplastic Syndrome Revealed by Systems Immunology in a Melanoma Patient Undergoing Anti-PD-1 Therapy
AR Greenplate, DB Johnson, M Roussel, MR Savona, JA Sosman, I Puzanov, PB Ferrell, JM Irish
Cancer immunology research 2016
Mesenchymal stromal cells in myeloid malignancies
T Schroeder, S Geyh, U Germing, R Haas
Blood Research 2016
The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype
AA Basiorka, KL McGraw, EA Eksioglu, X Chen, J Johnson, L Zhang, Q Zhang, BA Irvine, T Cluzeau, DA Sallman, E Padron, R Komrokji, L Sokol, RC Coll, AA Robertson, MA Cooper, JL Cleveland, LA ONeill, S Wei, AF List
Blood 2016
Stress and Non-Stress Roles of Inflammatory Signals during HSC Emergence and Maintenance
T Clapes, S Lefkopoulos, E Trompouki
Frontiers in immunology 2016
The phenotype, development and biological function of myeloid-derived suppressor cells: Molecular regulation of MDSCs
Y Zhao, T Wu, S Shao, B Shi, Y Zhao
OncoImmunology 2015
IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells
C Schinke, O Giricz, W Li, A Shastri, S Gordon, L Barreryo, T Bhagat, S Bhattacharyya, N Ramachandra, M Bartenstein, A Pellagatti, J Boultwood, A Wickrema, Y Yu, B Will, S Wei, U Steidl, A Verma
Blood 2015
Inactivation of DAP12 in PMN Inhibits TREM1-Mediated Activation in Rheumatoid Arthritis
X Chen, EA Eksioglu, JD Carter, N Fortenbery, SS Donatelli, J Zhou, J Liu, L Yang, D Gilvary, J Djeu, S Wei, S Papa
PloS one 2015
Immature myeloid cells directly contribute to skin tumor development by recruiting IL-17-producing CD4+ T cells
ML Ortiz, V Kumar, A Martner, S Mony, L Donthireddy, T Condamine, J Seykora, SC Knight, G Malietzis, GH Lee, M Moorghen, B Lenox, N Luetteke, E Celis, D Gabrilovich
Journal of Experimental Medicine 2015
Toll-like receptor signaling in hematopoietic homeostasis and the pathogenesis of hematologic diseases
J Cannova, PB S.J., J Zhang
Frontiers of Medicine 2015
COX-2 promotes metastasis in nasopharyngeal carcinoma by mediating interactions between cancer cells and myeloid-derived suppressor cells
ZL Li, SB Ye, LY OuYang, H Zhang, YS Chen, J He, QY Chen, CN Qian, XS Zhang, J Cui, YX Zeng, J Li
OncoImmunology 2015
The inflammatory microenvironment in MDS
L Yang, Y Qian, E Eksioglu, PK Epling-Burnette, S Wei
Cellular and Molecular Life Sciences 2015
Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes
I Gañán-Gómez, Y Wei, DT Starczynowski, S Colla, H Yang, M Cabrero-Calvo, ZS Bohannan, A Verma, U Steidl, G Garcia-Manero
Leukemia 2015
Myeloid Derived Suppressor Cells in Chronic Myeloid Leukemia
C Giallongo, N Parrinello, MV Brundo, SA Raccuia, MD Rosa, PL Cava, D Tibullo
Frontiers in Oncology 2015
Revisiting the case for genetically engineered mouse models in human myelodysplastic syndrome research
T Zhou, MC Kinney, LM Scott, SS Zinkel, VI Rebel
Blood 2015
Biology of the bone marrow microenvironment and myelodysplastic syndromes
EB Rankin, A Narla, JK Park, S Lin, KM Sakamoto
Molecular Genetics and Metabolism 2015
Loss of Tifab, a del(5q) MDS gene, alters hematopoiesis through derepression of Toll-like receptor-TRAF6 signaling
ME Varney, M Niederkorn, H Konno, T Matsumura, J Gohda, N Yoshida, T Akiyama, S Christie, J Fang, D Miller, A Jerez, A Karsan, JP Maciejewski, RA Meetei, J Inoue, DT Starczynowski
Journal of Experimental Medicine 2015
Expansion of myeloid derived suppressor cells correlates with number of T regulatory cells and disease progression in myelodysplastic syndrome
AO Kittang, S Kordasti, KE Sand, B Costantini, AM Kramer, P Perezabellan, T Seidl, KP Rye, KM Hagen, A Kulasekararaj, Ø Bruserud, GJ Mufti
OncoImmunology 2015
Clinical impact of CD200 expression in patients with acute myeloid leukemia and correlation with other molecular prognostic factors
Damiani D, Tiribelli M, Raspadori D, Sirianni S, Meneghel A, Cavalllin M, Michelutti A, Toffoletti E, Geromin A, Simeone E, Bocchia M, Fanin R
Oncotarget 2015
CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets
MK Gleason, JA Ross, ED Warlick, TC Lund, MR Verneris, A Wiernik, S Spellman, MD Haagenson, AJ Lenvik, MR Litzow, PK Epling-Burnette, BR Blazar, LM Weiner, DJ Weisdorf, DA Vallera, JS Miller
Blood 2014
Tasquinimod Modulates Suppressive Myeloid Cells and Enhances Cancer Immunotherapies in Murine Models
L Shen, A Sundstedt, M Ciesielski, KM Miles, M Celander, R Adelaiye, A Orillion, E Ciamporcero, S Ramakrishnan, L Ellis, R Fenstermaker, SI Abrams, H Eriksson, T Leanderson, A Olsson, R Pili
Cancer immunology research 2014
A phase II multicenter rabbit anti-thymocyte globulin trial in patients with myelodysplastic syndromes identifying a novel model for response prediction
RS Komrokji, AW Mailloux, DT Chen, MA Sekeres, R Paquette, WJ Fulp, C Sugimori, J Paleveda-Pena, JP Maciejewski, AF List, PK Epling-Burnette
Haematologica 2014
Pulmonary surfactant: an immunological perspective
ZC Chroneos, Z Sever-Chroneos, VL Shepherd
Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 2009

← Previous 1 2 3 … 7 8 Next →

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Picked up by 2 news outlets
Blogged by 1
Posted by 1 X users
Referenced in 67 patents
224 readers on Mendeley
See more details